Adverum Biotechnologies, Inc.
General ticker "ADVM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $77.6M (TTM average)
Adverum Biotechnologies, Inc. follows the US Stock Market performance with the rate: 16.8%.
Estimated limits based on current volatility of 1.0%: low 4.15$, high 4.23$
Factors to consider:
- Total employees count: 121 (-1.6%) as of 2023
- Top business risk factors: Operational and conduct risks, Product safety and efficacy risks, Litigation risks, Labor/talent shortage/retention, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.53$, 7.57$]
- 2025-12-31 to 2026-12-31 estimated range: [2.00$, 5.98$]
Financial Metrics affecting the ADVM estimates:
- Positive: with PPE of -0.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -98.03 <= 0.33
- Positive: 18.93 < Shareholder equity ratio, % of 39.32 <= 41.86
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term ADVM quotes
Long-term ADVM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $3.60MM | $1.00MM |
| Operating Expenses | $157.13MM | $127.59MM | $140.16MM |
| Operating Income | $-157.13MM | $-123.99MM | $-139.16MM |
| Non-Operating Income | $2.67MM | $5.75MM | $8.23MM |
| R&D Expense | $99.28MM | $77.68MM | $77.04MM |
| Income(Loss) | $-154.46MM | $-118.24MM | $-130.93MM |
| Taxes | $0.07MM | $-1.08MM | $0.00MM |
| Profit(Loss)* | $-154.54MM | $-117.17MM | $-130.93MM |
| Stockholders Equity | $181.52MM | $83.47MM | $70.71MM |
| Assets | $308.37MM | $173.01MM | $179.84MM |
| Operating Cash Flow | $-108.09MM | $-90.90MM | $-92.46MM |
| Capital expenditure | $11.82MM | $0.81MM | $0.39MM |
| Investing Cash Flow | $141.72MM | $96.88MM | $-41.89MM |
| Financing Cash Flow | $0.61MM | $0.07MM | $120.00MM |
| Earnings Per Share** | $-2.67 | $-2.02 | $-6.62 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.